11 January 2016 in Scientific Reports
Mutagenesis is an important tool to study gene regulation, model disease-causing mutations and for functional characterisation of proteins. Most of the current methods for mutagenesis involve multiple step procedures. One of the most accurate methods for genetically altering DNA is recombineering, which uses bacteria expressing viral recombination proteins. Recently, the use of in vitro seamless assembly systems using purified enzymes for multiple-fragment cloning as well as mutagenesis is gaining ground. Although these in vitro isothermal reactions are useful when cloning multiple fragments, for site-directed mutagenesis it is unnecessary. Moreover, the use of purified enzymes in vitro is not only expensive but also more inaccurate than the high-fidelity recombination inside bacteria. Here we present a single-step method, named REPLACR-mutagenesis (Recombineering of Ends of linearised PLAsmids after PCR), for creating mutations (deletions, substitutions and additions) in plasmids by in vivo recombineering. REPLACR-mutagenesis only involves transformation of PCR products in bacteria expressing Red/ET recombineering proteins. Modifications in a variety of plasmids up to bacterial artificial chromosomes (BACs; 144 kb deletion) have been achieved by this method. The presented method is more robust, involves fewer steps and is cost-efficient.
1 December 2016 in Journal of Endocrinology
Glycoprotein hormones are complex hormonally active macromolecules. Luteinizing hormone (LH) is essential for the postnatal development and maturation of the male gonad. Inactivating Luteinizing hormone beta (LHB) gene mutations are exceptionally rare and lead to hypogonadism that is particularly severe in males. We describe a family with selective LH deficiency and hypogonadism in two brothers. DNA sequencing of LHB was performed and the effects of genetic variants on hormone function and secretion were characterized by mutagenesis studies, confocal microscopy and functional assays. A 20-year-old male from a consanguineous family had pubertal delay, hypogonadism and undetectable LH. A homozygous c.118_120del (p.Lys40del) mutation was identified in the patient and his brother, who subsequently had the same phenotype. Treatment with hCG led to pubertal development, increased circulating testosterone and spermatogenesis. Experiments in HeLa cells revealed that the mutant LH is retained intracellularly and showed diffuse cytoplasmic distribution. The mutated LHB heterodimerizes with the common alpha-subunit and can activate its receptor. Deletion of flanking glutamic acid residues at positions 39 and 41 impair LH to a similar extent as deletion of Lys40. This region is functionally important across all heterodimeric glycoprotein hormones, because deletion of the corresponding residues in hCG, follicle-stimulating hormone and thyroid-stimulating hormone beta-subunits also led to intracellular hormone retention. This novel LHB mutation results in hypogonadism due to intracellular sequestration of the hormone and reveals a discrete region in the protein that is crucial for normal secretion of all human glycoprotein hormones.
1 March 2013 in Endocrine Abstracts
The classical model of GPCR activation entails the binding of a single ligand to a single receptor molecule, followed by transmembrane signal transduction to the appropriate G protein(s). The possibility of GPCRs functioning as dimers or oligomers still remains controversial, and is largely based on in vitro studies on transfected cells. The glycoprotein hormone receptors, including that of LH (LHCGR), differ from most GPCRs by their large extracellular ligand-binding domain distinct from the transmembrane signaling domain. Therefore, numerous LHCGR mutants are specifically devoid of either ligand binding or intracellular signaling. If such mutants are coexpressed in transfected cells, they can partially rescue ligand-evoked signaling, providing compelling evidence for functional complementation (or intermolecular co-operation) possibly through dimerization. We tested the physiological significance of this mode of receptor activation by co-expressing in BAC transgenic mice either a binding- or signaling deficient mutant of LHCGR, crossed into the LHCGR null background. Either of the mutant LHCGRs singularly expressed did not alter the hypogonadal phenotype of LHCGR knockout (KO) mice. However, when both mutants were coexpressed in the KO background, the eugonadal and fertile wild-type phenotype of male mice was restored. Interestingly, female mice co-expressing the two mutant receptors in the KO background remained hypogonadal and infertile. These findings indicate that binding- and signaling-deficient LHCGRs are able to partially recover the signaling that is sufficient for Leydig cell activation and fertility in male mice. Functional complementation in females is not sufficient to revert the hypogonadal KO phenotype, probably due to the higher receptor activation required (ovulatory LH peak), but it is also possible that only selected signaling pathways (biased agonism) are activated upon LHCGR functional complementation. Declaration of interest The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review. Declaration of funding This work was supported by the Wellcome Trust Programme Grant 082101/Z/07/Z, the BBSCR Project Grant BB/1008004/1 and a grant from The Academy of Finland.
27 August 2026 in bioRxiv
Pooled CRISPR screens coupled with single-cell RNA sequencing enable high-throughput functional interrogation of gene regulatory networks, yet systematic comparisons of CRISPR knockout (CRISPRko) and CRISPR interference (CRISPRi) remain limited. We established a single-cell CRISPRko workflow and benchmarked it against CRISPRi using 87 sgRNAs targeting 29 unfolded protein response genes. CRISPRko generated transcriptional phenotypes highly concordant with CRISPRi, and induced comparable pathway-level responses albeit with distinct on-target and off-target effects between modalities. While CRISPRi allows direct assessment of target gene repression, CRISPRko provides an effective complementary approach for complete loss-of-function studies, expanding the toolkit for single-cell functional genomics.